CVS

CVS Health stock reacts to upcoming earnings focus CVS Health (CVS) heads into its next earnings report with Wall Street expecting quarterly earnings of $1.62 per share, placing fresh attention on how each business segment is contributing.

CVS Health has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects.

Key points * Red Ribbon Week is a timely opportunity for adults to begin age-appropriate conversations about medication safety, substance misuse and mental health.

Besides Wall Street's top-and-bottom-line estimates for CVS Health (CVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.

It’s at least the fifth insurer to turn to the courts in a bid to hike its ratings for next year. The lawsuits make near-identical legal arguments. But CVS’ is more dramatic in its scope and alleged financial harm.

The average brokerage recommendation (ABR) for CVS Health (CVS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

CVS Health stock is down 16% from its 52-week high, and it trades at a relatively modest valuation.

The pharmacy retailer is expanding its assortment of toys and collectibles as adults fuel growth in those segments.

For questions about this article or underlying research, email [email protected].

CVS' third-quarter 2026 results face mixed segment trends, with Aetna's margin recovery and digital investments offering support amid persistent 340B pressures and membership declines.

The struggling pharmacy chain plans to give customers a reason to visit, even when they’re not picking up a prescription.

The struggling pharmacy chain plans to give customers a reason to visit even when they’re not picking up a prescription.